Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Teva shares slide on generic Copaxone fears

(Reuters) – Teva Pharmaceutical Industries shares slid five percent on Sunday after U.S. regulators approved a generic version of its top-selling multiple sclerosis drug and amid reports it was mulling a bid for rival Mylan. Teva’s Tel Aviv shares fell to 249.80 shekels ($64) late on Sunday, the first day of trading since both news […]

Read More »

Epizyme Announces Closing of Common Stock Offering

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced that the underwriters for its recently completed underwritten public offering of common stock have partially exercised their option to purchase additional shares of common stock from Epizyme. The underwriters purchased 701,448 shares from Epizyme at […]

Read More »

Athersys stroke treatment fails study, shares slide

Athersys Inc’s stem-cell therapy, its only product to reach human trials, failed a mid-stage study testing it as a treatment for a type of stroke, wiping off more than 40 percent of the company’s market value. Data showed on Friday that patients given the therapy, MultiStem, did not show a significant difference from those given […]

Read More »

Mylan Comments on Recent Media Speculation

Mylan Executive Chairman Robert J. Coury commented, “We note that there has been some media speculation with regard to a potential bid for Mylan by Teva and that this rumor has been circulating for some time. Although it has been company policy not to comment on such media speculation, given current circumstances, we believe it […]

Read More »

AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.

AbbVie Inc. today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics Inc. to 5 p.m., New York City time, on May 1, 2015. On April 17, 2015, AbbVie also voluntarily withdrew its initial Notification and Report Form under the Hart-Scott-Rodino […]

Read More »

IBM Acquires Heritage Group Portfolio Company Explorys

Explorys, a portfolio company of venture capital firm Heritage Group, has been acquired by IBM in an agreement signed April 13. In May 2012, big data company Explorys received a significant investment from the Heritage Healthcare Innovation Fund, a $167 million strategic venture fund that invests in businesses that reduce healthcare costs, improve outcomes and increase […]

Read More »

Ex-Teva CEO Becomes Chief of Start-Up Ovid Therapeutics As Orphan Drugs Come Into Focus

Stealth New York-based startup Ovid Therapeutics said this week that former Teva Pharmaceutical Industries Ltd.(TEVA) head Jeremy Levin will become its new chief executive, and that the company has recently inked its first deal with Danish drugmaker Lundbeck.  The Lundbeck plan now gives Ovid gaboxadol, a pill which it says may be effective in trials to test its two main disease targets, Angelman syndrome and […]

Read More »

ThromboGenics and VIB Form New Company to Research Roche-Rejected Cancer Drug

ThromboGenics NV (TBGNF), a biopharmaceutical company based in Leuven, Belgium, announced that it is teaming up with VIB, a life sciences institute in Flanders (Belgium), to found Oncurious NV, an oncology company.  Oncurious will focus on developing TB-403 for the treatment of pediatric brain tumors. TB-403 is a monoclonal antibody that opposes placental growth factor (PIGF). PIGF is observed in several […]

Read More »

Obamacare, Move From Fee-For-Service Boosts UnitedHealth By $2B

UnitedHealth Group (UNH) says its revenue this year will increase by $2 billion more than earlier projected for 2015 thanks in part to its expansion on public exchanges under the Affordable Care Act and its push to more value-based care contracts with doctors and hospitals. The outlook, which includes increased earnings projections for this year […]

Read More »

Aduro Biotech Launches $119 Million IPO with Hot Cancer Tech

BERKELEY, Calif.–(BUSINESS WIRE)–Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a price to the public of $17.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the initial […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom